For one rare type of lung cancer, Pfizer pill reduces progression by 81%; Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials

Taking stock of the drug industry, from the lab to the medicine chest

May 31, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

AP/Business Wire STAT+ | For one rare type of lung cancer, Pfizer pill reduces progression by 81% It's a stunning number, especially considering that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug. By Matthew Herper FDA approves Moderna's RSV vaccine, its second licensed product The company's RSV vaccine, which will be marketed under the name mResvia, was approved for adults 60 and older. By Helen Branswell What to watch for in the crucial FDA meeting on MDMA therapy for PTSD As Lykos Therapeutics seeks a landmark approval of psychedelic therapy for PTSD, it will face scrutiny from an FDA advisory panel next week. By Olivia Goldhill courtesy Ionis Pharmaceuticals STAT+ | Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials Ionis plans to use the findings to apply for FDA approval of donidalorsen by the end of this year for treating a rare genetic disease. By Jonathan Wosen STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser